Split Fed. Circ. Backs PTAB Ax Of Genentech Cancer Drug IP
A split Federal Circuit on Friday affirmed the Patent Trial and Appeal Board's decision invalidating parts of Genentech Inc.'s patent on the blockbuster cancer drug Avastin for being anticipated or obvious...To view the full article, register now.
Already a subscriber? Click here to view full article